<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    16291416
   </pmid>
   <datecreated>
    <year>
     2005
    </year>
    <month>
     11
    </month>
    <day>
     18
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2006
    </year>
    <month>
     11
    </month>
    <day>
     13
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2006
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0149-2918
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       27
      </volume>
      <issue>
       9
      </issue>
      <pubdate>
       <year>
        2005
       </year>
       <month>
        Sep
       </month>
      </pubdate>
     </journalissue>
     <title>
      Clinical therapeutics
     </title>
     <isoabbreviation>
      Clin Ther
     </isoabbreviation>
    </journal>
    <articletitle>
     Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study.
    </articletitle>
    <pagination>
     <medlinepgn>
      1432-43
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">
      Few large randomized controlled trials have assessed the value of adding insulin to an oral antidiabetic drug regimen.
     </abstracttext>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      This trial compared the efficacy and safety of biphasic insulin aspart 30/70 (BIAsp 30) plus pioglitazone (n = 93), glibenclamide (glyburide) plus pioglitazone (n = 91), or BIAsp 30 monotherapy (n = 97).
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      This 18-week, multinational, multicenter, randomized, open-label, parallel-group trial involved 281 patients with type 2 diabetes (60% male; mean age, 56 years; mean body mass index, 29.5 kg/m2) with inadequate glycemic control (mean glycosylated hemoglobin [HbA(1c)], 9.5%; range, 7.4%-14.7%) on glibenclamide monotherapy or combination therapy. The primary objective was to compare end-of-trial HbA(1c) among the 3 treatment groups. Fasting and mean 7- and 8-point blood glucose profiles, blood lipid levels, plasminogen activator inhibitor levels, adverse events, and hypoglycemia frequency were also compared. Patients using BIAsp 30 (alone or with pioglitazone) were injected twice daily (immediately before breakfast and dinner). Pioglitazone (30 mg/d) and glibenclamide (5-15 mg/d) were taken orally once daily with or immediately after breakfast.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      At the end of the trial, HbA(1c) was significantly lower for the BIAsp 30 plus pioglitazone group than for the glibenclamide plus pioglitazone group (mean [SD], -0.64% [0.23%]; P = 0.005) and the BIAsp 30 monotherapy group (-0.60% [0.22%]; P = 0.008). Mean (SD) fasting blood glucose (before breakfast) was significantly lower for BIAsp 30 plus pioglitazone than for glibenclamide plus pioglitazone (153 [45] mg/dL vs 169 [65] mg/dL, respectively; P = 0.012). Each time point on the 8-point blood glucose profile was lower for BIAsp 30 plus pioglitazone than for glibenclamide plus pioglitazone (P &lt; 0.001 to P &lt; 0.05). No major hypoglycemic episodes were reported, and the absolute rate of hypoglycemic events was low (&lt;1 event/patient-week) in the BIAsp-only group. Edema was reported in &lt; or =9% of patients in each treatment group, but no occurrence was classified as serious. Weight gain (mean, 4.0 kg) was more common in the BIAsp plus pioglitazone group (8%); however, this was consistent with improved glycemic control and is similar to that reported in other pioglitazone trials.
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      BIAsp 30 plus pioglitazone provided an efficacious and well-tolerated treatment alternative to glibenclamide plus pioglitazone or BIAsp 30 alone in this population of patients who previously were not well controlled on glibenclamide monotherapy or combination therapy.
     </abstracttext>
    </abstract>
    <affiliation>
     Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem, Israel. ntv502@netvision.net.il
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Raz
      </lastname>
      <forename>
       Itamar
      </forename>
      <initials>
       I
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Stranks
      </lastname>
      <forename>
       Stephen
      </forename>
      <initials>
       S
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Filipczak
      </lastname>
      <forename>
       Robert
      </forename>
      <initials>
       R
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Joshi
      </lastname>
      <forename>
       Pankaj
      </forename>
      <initials>
       P
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Lertoft
      </lastname>
      <forename>
       Benedikte
      </forename>
      <initials>
       B
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Rastam
      </lastname>
      <forename>
       Jacob
      </forename>
      <initials>
       J
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Chow
      </lastname>
      <forename>
       Chun-Chung
      </forename>
      <initials>
       CC
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Shaban
      </lastname>
      <forename>
       Joseph
      </forename>
      <initials>
       J
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Comparative Study
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Multicenter Study
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     Clin Ther
    </medlineta>
    <nlmuniqueid>
     7706726
    </nlmuniqueid>
    <issnlinking>
     0149-2918
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Blood Glucose
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Hemoglobin A, Glycosylated
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Hypoglycemic Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Thiazolidinediones
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Triglycerides
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      10238-21-8
     </registrynumber>
     <nameofsubstance>
      Glyburide
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      11061-68-0
     </registrynumber>
     <nameofsubstance>
      Insulin
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      111025-46-8
     </registrynumber>
     <nameofsubstance>
      pioglitazone
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Blood Glucose
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Diabetes Mellitus, Type 2
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Therapy, Combination
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Glyburide
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hemoglobin A, Glycosylated
     </descriptorname>
     <qualifiername majortopicyn="N">
      metabolism
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hypoglycemic Agents
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Insulin
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      analogs &amp; derivatives
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Thiazolidinediones
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Time Factors
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Triglycerides
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Weight Gain
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug effects
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="accepted">
     <year>
      2005
     </year>
     <month>
      6
     </month>
     <day>
      15
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2005
     </year>
     <month>
      11
     </month>
     <day>
      18
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2006
     </year>
     <month>
      11
     </month>
     <day>
      14
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2005
     </year>
     <month>
      11
     </month>
     <day>
      18
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pii">
     S0149-2918(05)00166-9
    </articleid>
    <articleid idtype="doi">
     10.1016/j.clinthera.2005.09.001
    </articleid>
    <articleid idtype="pubmed">
     16291416
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

